RSNA 2005

Nov 26, 2005

Attendees navigate the maze to receive their RSNA badges.

none
Latest in Home
Football Players Scrimmage
Adding AI to MRI improves return to play classification frameworks
December 10, 2025
Runner Street Thumbnail Adobe Augustas Cetkauskas
Marathon training does not have long-term negative effects on heart
December 10, 2025
Scans in a 73-year-old man with biochemically recurrent prostate cancer (prostate-specific antigen level of 0.5 ng/mL) who underwent PET/CT with 9.4 mCi of F-18 piflufolastat and a second PET/CT examination with 8.1 mCi of copper 61-NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid)–prostate-specific membrane antigen for imaging and therapy (Cu-61 PSMA I&T) 24 days apart, with no intervening therapy. Maximum intensity projection (MIP) images obtained (A) 1 hour after F-18 piflufolastat administration and (B) 1, (C) 2, and (D) 4 hours after Cu-61 PSMA I&T administration are shown. Physiologic uptake is seen in the lacrimal glands, salivary glands, liver, spleen, kidneys, ureters, and bladder. Pathologic uptake in pelvic nodal metastases is labeled with arrows. The F-18 piflufolastat PET/CT MIP image reveals two avid pelvic nodal metastases (arrows). Cu-61 PSMA I&T PET/CT scans demonstrate three avid pelvic nodal metastases on 1-hour and 2-hour images (arrows); five avid pelvic nodal metastases were suspected on the 4-hour image (arrows).
Phase I trial reveals the potential of a new PSMA-PET tracer
December 9, 2025
Images depict a 50-year-old woman with a lesion detected during screening ultrasound. (A) Transverse and (B) longitudinal images reveal a 0.5-cm hypoechoic lesion (arrow) in the left breast. (C) Transverse color Doppler ultrasound image does not show an increase in vascularity. Two readers classified the lesion as a mass, whereas two others categorized it as a nonmass lesion, leading to its designation as a controversial nonmass lesion. Ultrasound-guided core needle biopsy and subsequent pathologic examination confirmed a nonproliferative breast change.
Radiologists can designate nonmass lesions on breast ultrasound
December 9, 2025
More in Home
Adding AI to MRI improves return to play classification frameworks
By Kate Madden Yee
Predicting when athletes can safely return to play after an injury is key.
December 10, 2025
Football Players Scrimmage
Marathon training does not have long-term negative effects on heart
By Amerigo Allegretto
Echocardiography shows that endurance training by marathon runners does not have long-term negative effects on the heart.
December 10, 2025
Runner Street Thumbnail Adobe Augustas Cetkauskas
Phase I trial reveals the potential of a new PSMA-PET tracer
By Will Morton
The radiotracer detected more lesions in men with metastatic disease than F-18 piflufolastat.
December 9, 2025
Scans in a 73-year-old man with biochemically recurrent prostate cancer (prostate-specific antigen level of 0.5 ng/mL) who underwent PET/CT with 9.4 mCi of F-18 piflufolastat and a second PET/CT examination with 8.1 mCi of copper 61-NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid)–prostate-specific membrane antigen for imaging and therapy (Cu-61 PSMA I&T) 24 days apart, with no intervening therapy. Maximum intensity projection (MIP) images obtained (A) 1 hour after F-18 piflufolastat administration and (B) 1, (C) 2, and (D) 4 hours after Cu-61 PSMA I&T administration are shown. Physiologic uptake is seen in the lacrimal glands, salivary glands, liver, spleen, kidneys, ureters, and bladder. Pathologic uptake in pelvic nodal metastases is labeled with arrows. The F-18 piflufolastat PET/CT MIP image reveals two avid pelvic nodal metastases (arrows). Cu-61 PSMA I&T PET/CT scans demonstrate three avid pelvic nodal metastases on 1-hour and 2-hour images (arrows); five avid pelvic nodal metastases were suspected on the 4-hour image (arrows).
Radiologists can designate nonmass lesions on breast ultrasound
By Amerigo Allegretto
Breast radiologists achieved moderate to substantial interreader agreement for classifying nonmass lesions on ultrasound.
December 9, 2025
Images depict a 50-year-old woman with a lesion detected during screening ultrasound. (A) Transverse and (B) longitudinal images reveal a 0.5-cm hypoechoic lesion (arrow) in the left breast. (C) Transverse color Doppler ultrasound image does not show an increase in vascularity. Two readers classified the lesion as a mass, whereas two others categorized it as a nonmass lesion, leading to its designation as a controversial nonmass lesion. Ultrasound-guided core needle biopsy and subsequent pathologic examination confirmed a nonproliferative breast change.
Long COVID's neurological effects persist
By Kate Madden Yee
Long COVID is typically defined as persistent symptoms beyond four weeks from onset of the illness.
December 9, 2025
Coronavirus
MRI proves effective for tracking results of obesity interventions
By Kate Madden Yee
MRI is a powerful tool to monitor skeletal muscle adaptations during lifestyle interventions for obesity, researchers noted.
December 8, 2025
Obesity Text2
TVR-PET/CT shows promise in primary hyperparathyroidism
By Will Morton
Gallium-68 trivehexin PET/CT was superior for identifying lesions over technetium-99m sestamibi SPECT.
December 8, 2025
Phpt
ACR talks BI-RADS version 2025 with AuntMinnie
By Amerigo Allegretto
ACR members discussed the need to release the latest version of BI-RADS and what changes breast radiologists can expect.
December 8, 2025
Acr Logo 2023 400
ACR's Ted Burnes talks advocacy in radiology with AuntMinnie
By Amerigo Allegretto
Ted Burnes from the American College of Radiology spoke with AuntMinnie on achievements in advocacy and what 2026 may bring.
December 8, 2025
Screenshot (91)
PiB-PET/CT detects subtypes in cardiac amyloidosis
By Will Morton
PiB-PET/CT shows strong promise as a next-generation diagnostic tool for cardiac amyloidosis.
December 5, 2025
Heart
HPI: 13.5B mL of contrast media administered from 2011 to 2024
By Kate Madden Yee
The findings are sobering, as contrast use contributes to environmental pollution.
December 5, 2025
Contrast Injector
AI ultrasound tool could reduce unnecessary biopsies by 60%
By Amerigo Allegretto
An AI tool could help reduce unnecessary breast biopsies, but should be used in conjunction with radiologist decision-making.
December 5, 2025
2025 12 05 Ai Decision Support Tool Ultrasound Thumbnail
Page 1 of 190
Next Page